Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance

Kyle, Robert A., Larson, Dirk R., Therneau, Terry M., Dispenzieri, Angela, Kumar, Shaji, Cerhan, James R., Rajkumar, S. Vincent·2018·New England Journal of Medicine
DOI 10.1056/nejmoa1709974

Cited by (646)

Items 101–200 of 646

  1. The Wide Spectrum of Pathophysiologic Mechanisms of Paraproteinemic Neuropathy
    Jean‐Michel Vallat, Mathilde Duchesne, Philippe Corcia, Laurence Richard, Karima Ghorab, Laurent Magy, Stéphane Mathis · 2020 · Neurology
  2. Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment
    Artem Oganesyan, Andrew Gregory, Florent Malard, Nerses Ghahramanyan, Mohamad Mohty, Dickran Gano Kazandjian, Arsène MEKINIAN, Yervand K. Hakobyan · 2022 · Frontiers in Immunology
  3. An updated AL-base reveals ranked enrichment of immunoglobulin light chain variable genes in AL amyloidosis
    Gareth J. Morgan, Allison N. Nau, Sherry Wong, Brian Spencer, Yun Shen, Axin Hua, Matthew J. Bullard, Vaishali Sanchorawala, Tatiana B. Prokaeva · 2024 · Amyloid
  4. Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma
    Francesco Maura, Ola Landgren, Gareth John Morgan · 2020 · Clinical Cancer Research
  5. Lifetime Pesticide Use and Monoclonal Gammopathy of Undetermined Significance in a Prospective Cohort of Male Farmers
    Jonathan N. Hofmann, Laura E. Beane Freeman, Kazunori Murata, Gabriella Andreotti, Joseph J. Shearer, Katie L. Thoren, Lakshmi V. Ramanathan, Christine Gibson Parks, Stella Koutros, Catherine Chase Lerro et al. · 2021 · Environmental Health Perspectives
  6. Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)
    Pang Li, S. Vincent Rajkumar, Prashant Kapoor, Francis K. Buadi, Angela A. Dispenzieri, Morie Abraham Gertz, Martha Q. Lacy, Robert A. Kyle, Shaji Kunnathu Kumar · 2021 · Blood Cancer Journal
  7. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events
    Ola Landgren · 2021 · Hematology
  8. Smoldering Multiple Myeloma
    S. Vincent Rajkumar, Peter Leif Bergsagel, Shaji Kunnathu Kumar · 2023 · Hematology/Oncology Clinics of North America
  9. Monoclonal gammopathy in rheumatic diseases
    Yue Yang, Long Chen, Yuan Jia, Yang Liu, Lei Wen, Yaoxian Liang, Yuan An, Shi Chen, Yin Su, Zhanguo Li · 2018 · Clinical Rheumatology
  10. A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity
    Matteo Da Vià, Bachisio Ziccheddu, Akihiro Maeda, Filippo Bagnoli, Giulia Perrone, Niccolò Bolli · 2020 · HemaSphere
  11. Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
    Hanley N. Abramson · 2023 · International Journal of Molecular Sciences
  12. Clonal Evolution of Multiple Myeloma—Clinical and Diagnostic Implications
    Aleksander Salomon‐Perzyński, Krzysztof Jamroziak, Eliza Głodkowska‐Mrówka · 2021 · Diagnostics
  13. Prevalence of monoclonal gammopathy of undetermined significance in a large population with annual medical check-ups in China
    Jianhua Han, Jinuo Wang, Yuelun Zhang, Xinxin Cao, Daobin Zhou, Tengda Xu, Wei Su, Jian Li · 2020 · Blood Cancer Journal
  14. The Molecular Pathogenesis of Multiple Myeloma
    Niccolò Bolli, Giovanni Martinelli, Claudio Cerchione · 2020 · Hematology Reports
  15. It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma
    Ruth Choa, Cristina Panaroni, Roma Bhatia, Noopur S Raje · 2023 · Blood Advances
  16. Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry
    Yann Nguyen, Jérôme Stirnemann, Florent Lautredoux, Bérengère Cador, Monia Bengherbia, Karima Yousfi, Dalil Hamroun, Leonardo M. Astudillo, Thierry Billette de Villemeur, Anaïs Brassier et al. · 2020 · International Journal of Molecular Sciences
  17. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases
    Giada Bianchi, Shaji Kunnathu Kumar · 2020 · Hematology/Oncology Clinics of North America
  18. CHIPing away the progression potential of CHIP: A new reality in the making
    Zhuoer Xie, Amer Methqal Zeidan · 2022 · Blood Reviews
  19. Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma
    Tarek H. Mouhieddine, Chidimma Nzerem, Robert Allyn Redd, Andrew J Dunford, Matthew Joseph Leventhal, Romanos Sklavenitis‐Pistofidis, Sabrin Tahri, Habib El‐Khoury, David P. Steensma, Benjamin L. Ebert et al. · 2023 · Cancer Research Communications
  20. Paraproteinemic keratopathy associated with monoclonal gammopathy of undetermined significance ( MGUS ): clinical findings in twelve patients including recurrence after keratoplasty
    Pavlína Skalická, Ľubica Ďuďáková, Michalis Palos, Lukas J. Huna, Cerys J. Evans, Gabriela Mahelková, Martin Meliska, Tomáš Stopka, Stephen J. Tuft, Petra Lišková · 2019 · Acta Ophthalmologica
  21. Serum Free Light Chain Assay in Monoclonal Gammopathic Manifestations
    Won S. Lee, Gurmukh Singh · 2019 · Laboratory Medicine
  22. Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma
    Jingjing Pu, Ting Liu, Amit Sharma, Liping Jiang, Feng Wei, Xiubao Ren, Ingo G.H. Schmidt‐Wolf, Jian Hou · 2024 · Experimental Hematology and Oncology
  23. An approach to the diagnosis and management of multiple myeloma
    Fatima Bibi Fazel, Fatima Bassa · 2019 · South African Medical Journal
  24. A Fresh Perspective on Monoclonal Gammopathies of Renal Significance
    Pièrre Aucouturier, Vivette Denise D’Agati, Pierre Marie Ronco · 2021 · Kidney International Reports
  25. New Developments in Myeloma Treatment and Response Assessment
    Françoise Kraeber‐Bodéré, Bastien Jamet, Davide Bezzi, Elena Zamagni, Philippe Moreau, Cristina Nanni · 2023 · Journal of Nuclear Medicine
  26. A risk‐stratification model based on the initial concentration of the serum monoclonal protein and MYD 88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders
    Marzia Varettoni, Silvia Zibellini, Emanuela Boveri, Catherine Klersy, Chiara Candido, Sara Rattotti, Virginia Valeria Ferretti, Irene Defrancesco, Silvia Mangiacavalli, Maria Elena Nizzoli et al. · 2019 · British Journal of Haematology
  27. Multiple myeloma: Detection of free monoclonal light chains by modified immunofixation electrophoresis with antisera against free light chains
    Dorian Willhite, Ahmed Arfa, Thomas G. Cotter, Natasha M. Savage, Roni J. Bollag, Gurmukh Singh · 2021 · Practical Laboratory Medicine
  28. From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance
    Andrea Visentin, Stefano Pravato, Francesca Castellani, Marta Campagnolo, Francesco Angotzi, Chiara Adele Cavarretta, Alessandro Cellini, Valeria Ruocco, Alessandro Salvalaggio, Alessandra Tedeschi et al. · 2022 · Cancers
  29. Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
    Catharina Muylaert, Lien Ann Van Hemelrijck, Anke Maes, Kim De Veirman, Eline Menu, Karin Vanderkerken, Elke De Bruyne · 2022 · Frontiers in Oncology
  30. Monoclonal gammopathy of undetermined significance: evaluation, risk assessment, management, and beyond
    Jithma P. Abeykoon, Reema K. Tawfiq, Shaji Kunnathu Kumar, Stephen Maxted Ansell · 2022 · Faculty Reviews
  31. Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations
    Abhishek Avinash Mangaonkar, Mrinal M. Patnaik · 2023 · American Journal of Hematology
  32. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance
    Elías Sæbjörn Eyþórsson, Sæmundur Rögnvaldsson, Sigrún Þorsteinsdóttir, Thorir Einarsson Long, Elín Ruth Reed, Guðrún Ásta Sigurðardóttir, Brynjar Viðarsson, Pall Torfi Onundarson, Bjarni Agnar Agnarsson, Margrét Sigrún Sigurðardóttir et al. · 2024 · Annals of Internal Medicine
  33. Waldenström macroglobulinemia treatment algorithm 2018
    Morie Abraham Gertz · 2018 · Blood Cancer Journal
  34. From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression
    Carmelo Gurnari, Emiliano Fabiani, Giulia Falconi, Serena Travaglini, Tiziana Ottone, Antonio Cristiano, Maria Teresa Voso · 2021 · Biology
  35. Molecular Pathogenesis of Multiple Myeloma
    Maura, Francesco, Bergsagel, Peter Leif · 2024 · Hematology/Oncology Clinics of North America
  36. Treatment of Patients with Monoclonal Gammopathy of Clinical Significance
    David Fernando Moreno, Laura Rosiñol, María Teresa Cibeira, Joan Bladé, Carlos Fernández de Larrea · 2021 · Cancers
  37. From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy
    Seyed Esmaeil Ahmadi, Elahe Rahimian, Samira Rahimi, Bahman Zarandi, Mehran Bahraini, Maral Soleymani, Seyed Mehrab Safdari, Ashkan Shabannezhad, Niloofar Jaafari, Majid Safa · 2024 · Biomarker Research
  38. Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies
    Shaji Kunnathu Kumar, Dirk R. Larson, Angela A. Dispenzieri, Terry M. Therneau, David L. Murray, Peter Leif Bergsagel, Robert A. Kyle, S. Vincent Rajkumar · 2019 · Blood Cancer Journal
  39. Updates in the Diagnosis and Management of AL Amyloidosis
    Joselle Cook, Eli Muchtar, Rahma M. Warsame · 2020 · Current Hematologic Malignancy Reports
  40. Light Chain Predominant Intact Immunoglobulin Monoclonal Gammopathy Disorders: Shorter Survival in Light Chain Predominant Multiple Myelomas
    Gurmukh Singh, Hongyan Xu · 2020 · Laboratory Medicine
  41. Genomics define malignant transformation in myeloma precursor conditions
    Maura, Francesco, Bergsagel, P. Leif, Ziccheddu, Bachisio, Kumar, Shaji, Maclachlan, Kylee, Derkach, Andriy, Garces, Juan-Jose, Firestone, Ross, Braggio, Esteban, Asmann, Yan et al. · 2026 · Journal of Clinical Oncology
  42. New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies
    Karolina Woziwodzka, David H. Vesole, Jolanta Małyszko, Krzysztof Batko, Artur J. Jurczyszyn, Ewa Koc‐Żórawska, Marcin Krzanowski, Jacek Stanisław Małyszko, Marcin Żórawski, Anna Waszczuk‐Gajda et al. · 2020 · Journal of Clinical Medicine
  43. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential
    Yong Li, Zijun Yidan Xu-Monette, Jeremy S. Abramson, Aliyah R. Sohani, Govind Bhagat, Alexandar Tzankov, Carlo Visco, Shanxiang Zhang, Karen Dybkær, Zenggang Pan et al. · 2022 · Blood Advances
  44. Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia
    Ramón García‐Sánz, Marzia Varettoni, Cristina Jiménez, Simone Ferrero, Stéphanie Poulain, Jesús F. San Miguel, Maria Luisa Guerrera, Daniela Drandi, Tina Bagratuni, Mary L. McMaster et al. · 2023 · Seminars in Hematology
  45. Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?
    Christian Brieghel, Veerle Galle, Rudi Agius, Caspar da Cunha‐Bang, Michael Asger Andersen, Philip Vlummens, Mattias Mattsson, Richard Rosenquist, Karin Ekstrom Ekstroem Smedby, Carmen Herling et al. · 2022 · European Journal Of Haematology
  46. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma
    Dávid Kegyes, Diana Gulei, Rareş Drulă, Diana Cenariu, Adrian Bogdan Țigu, Delia Monica Dima, Alina Tănase, Sorina Nicoleta BADELITA, Anca Dana Buzoianu, Stefan Octavian Ciurea et al. · 2023 · Blood Reviews
  47. Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population
    2023
  48. Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review
    Charlotte Cosemans, Bénedith Oben, Ingrid Arijs, Annick Daniëls, Jeroen Declercq, Kimberly Vanhees, Guy Froyen, Brigitte Maes, Jeroen Mebis, Jean‐Luc Rummens · 2018 · Clinical Lymphoma Myeloma & Leukemia
  49. Hidden analyses: a review of reporting practice and recommendations for more transparent reporting of initial data analyses
    on behalf of the Topic Group “Initial Data Analysis” of the STRATOS Initiative (STRengthening Analytical Thinking for Observational Studies, ), Marianne Huebner, Werner Vach, Saskia le Cessie, Carsten Oliver Schmidt, Lara Lusa · 2020 · BMC Medical Research Methodology
  50. Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1
    Adrien Bosseboeuf, Nicolas Mennesson, Sophie Allain‐Maillet, Anne Tallet, Éric Piver, Olivier Decaux, Caroline Moreau, Philippe Moreau, Philippe Lehours, Françis Mégraud et al. · 2020 · Cancers
  51. Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients
    Adrien Bosseboeuf, Célia Seillier, Nicolas Mennesson, Sophie Allain‐Maillet, Maeva Fourny, Anne Tallet, Éric Piver, Philippe Lehours, Françis Mégraud, Laureline Berthelot et al. · 2020 · Frontiers in Immunology
  52. Multiple Myeloma as a Bone Disease? The Tissue Disruption-Induced Cell Stochasticity (TiDiS) Theory
    Jean‐Pascal Capp, Régis Bataille · 2020 · Cancers
  53. Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions
    Chao-Chao Yu, Yi Li, Zhao-Jun Cheng, X. L. Wang, Wei Mao, Yingwen Zhang · 2022 · Frontiers in Pharmacology
  54. Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance
    Brian Schwartz, Morten Schou, Frederick L. Ruberg, Dane Rucker, Ji‐Hoon Choi, Omar K. Siddiqi, Kevin M. Monahan, Lars Køber, Gunnar Gislason, Christian Tobias Torp-Pedersen et al. · 2022 · JACC CardioOncology
  55. Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article
    Munawwar Hussain, Sarvari Venkata Yellapragada, Samer Al Hadidi · 2023 · Blood and Lymphatic Cancer Targets and Therapy
  56. Genomic profiling to contextualize the results of intervention for smoldering multiple myeloma
    Kazandjian, Dickran, Diamond, Benjamin, Papadimitriou, Marios, Hill, Elizabeth, Sklavenitis-Pistofidis, Romanos, Ziccheddu, Bachisio, Blaney, Patrick, Chojnacka, Monika, Durante, Michael, Maclachlan, Kylee et al. · 2024 · Clinical Cancer Research
  57. Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection
    Alissa Visram, Dirk R. Larson, Aaron D. Norman, Angela A. Dispenzieri, David L. Murray, Robert A. Kyle, S. Vincent Rajkumar, Susan L. Slager, Shaji Kunnathu Kumar, Celine M. Vachon · 2024 · Blood
  58. Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men
    Kara I. Cicero, Maureen Joffe, Moosa Patel, Codruta C. Chiuzan, Audrey Pentz, Paul Ruff, Suzanne Lentzsch, Siyang Leng, Judith S. Jacobson, Timothy Richard Rebbeck et al. · 2022 · Cancer Epidemiology Biomarkers & Prevention
  59. Potential diagnostic value of circulating miRNA for multiple myeloma: A meta-analysis
    Shuaishuai Gao, Yanjun Wang, Guoxun Zhang, Wenting Zhang · 2020 · Journal of bone oncology
  60. Monoclonal Gammopathy and Its Association with Progression to Kidney Failure and Mortality in Patients with CKD
    Janina Paula T. Sy‐Go, Simon Moubarak, Lisa E. Vaughan, Nattawat Klomjit, Jason K. Viehman, Fernando Custodio Fervenza, Ladan Zand · 2023 · Clinical Journal of the American Society of Nephrology
  61. The Diagnostic and Therapeutic Implications of Phenocopies and Mimics of Hypertrophic Cardiomyopathy
    Athanasios Bakalakos, Emanuele Monda, Perry M Elliot · 2024 · Canadian Journal of Cardiology
  62. Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom’s Macroglobulinemia
    Romanos Sklavenitis‐Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, Ting Wu, Nicholas Tsakmaklis, Michelle P. Aranha, Zachary R. Hunter, Alaa Kassim Ali, Junko Tsuji, Nicholas J. Haradhvala et al. · 2025 · Nature Communications
  63. Challenges in Gaucher disease: Perspectives from an expert panel
    Gregory Alex Grabowski, Priya Sunil Kishnani, Roy N. Alcalay, Sasapin Grace Prakalapakorn, Barry E. Rosenbloom, Dominick A. Tuason, Neal J. Weinreb · 2025 · Molecular Genetics and Metabolism
  64. A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor
    Jonathan N. Hofmann, Ola Landgren, Rebecca Landy, Troy J. Kemp, Loredana Santo, Charlene M. McShane, Joseph J. Shearer, Qing Lan B, Nathaniel Rothman, Lígia A. Pinto et al. · 2019 · JNCI Cancer Spectrum
  65. Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period
    Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Μαρία Ρούσσου, Nikolaos Kanellias, Despina Fotiou, Magdalini Migkou, Evangelos Eleutherakis‐Papaiakovou, Maria Gavriatopoulou, Efstathios Kastritis, Meletios Athanasios Dimopoulos · 2020 · Annals of Hematology
  66. B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS
    Kristin Schmidt, Ulrike Sack, Robin Graf, Wiebke Winkler, Oliver Popp, Philipp Mertins, Thomas G. Sommermann, Christine Kocks, Klaus Rajewsky · 2020 · Frontiers in Immunology
  67. Whole-body magnetic resonance imaging (WBMRI) versus whole-body computed tomography (WBCT) for myeloma imaging and staging
    M Treitl, Jens Ricke, Andrea Baur‐Melnyk · 2021 · Skeletal Radiology
  68. Harnessing the Immune System to Fight Multiple Myeloma
    Jakub Krejcik, Mike Bogetofte Barnkob, Charlotte Guldborg Nyvold, Thomas Stauffer Larsen, Torben Barington, Niels Abildgaard · 2021 · Cancers
  69. Paraproteinemia and neuropathy
    Haruki Koike, Masahisa Katsuno · 2021 · Neurological Sciences
  70. Light Chain–Predominant Multiple Myeloma Subgroup: Impaired Renal Function Correlates with Decreased Survival
    Gurmukh Singh, Natasha M. Savage, Anand P. Jillella, Roni J. Bollag · 2021 · Laboratory Medicine
  71. Investigation and management of the monoclonal gammopathy of undetermined significance
    Simon Stern, Satarupa Chaudhuri, Mark Trehane Drayson, Sarah Henshaw, Kamaraj Karunanithi, Fenella M Willis, the Haemato‐Oncology Task Force of the British Society for Haematology and the UK Myeloma Forum · 2023 · British Journal of Haematology
  72. A gene signature can predict risk of MGUS progressing to multiple myeloma
    Fumou Sun, Yan Cheng, Jun Ying, David E. Mery, Samer Al Hadidi, Visanu Wanchai, Eric R. Siegel, Hongwei Xu, Dongzheng Gai, Cody Ashby et al. · 2023 · Journal of Hematology & Oncology
  73. The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans
    Francesco Maura, David Glen Coffey, Caleb K. Stein, Esteban Braggio, Bachisio Ziccheddu, Meaghen E. Sharik, Megan T. Du, Yuliza Tafoya Alvarado, Chang-Xin Shi, Yuan Xiao Zhu et al. · 2024 · Nature Communications
  74. Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma
    Matteo Da Vià, Francesca Lazzaroni, Antonio Matera, Alessio Marella, Akihiro Maeda, Claudio De Magistris, Loredana Pettine, Antonio Giovanni Solimando, Vanessa Desantis, Giuseppe M. Peretti et al. · 2025 · Blood
  75. Temporal genomic dynamics shape clinical trajectory in multiple myeloma
    Maura, Francesco, Kaddoura, Marcella, Poos, Alexandra M., Baughn, Linda B., Ziccheddu, Bachisio, Bärtsch, Marc-Andrea, Cirrincione, Anthony, Maclachlan, Kylee, Chojnacka, Monika, Diamond, Benjamin et al. · 2025 · Nature Genetics
  76. Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction study
    Subhayan Chattopadhyay, Hauke Thomsen, Miguel Inácio da Silva Filho, Niels Weinhold, Per Hoffmann, Markus Maria Nöthen, Marina Arendt, Karl‐Heinz Jöckel, Börge Schmidt, Sonali Pechlivanis et al. · 2018 · Molecular Medicine
  77. Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects
    Shivani Seth, Saurabh Zanwar, Linh Vu, Prashant Kapoor · 2020 · Current Hematologic Malignancy Reports
  78. Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations
    Yunhui Xiang, Liu-Yun Zhang, Pinpin Xiang, Juan Zhang · 2021 · Frontiers in Oncology
  79. Waldenström’s Macroglobulinemia: An Exploration into the Pathology and Diagnosis of a Complex B-Cell Malignancy
    Elham Askari, Sara Rodríguez, Ramón García‐Sánz · 2021 · Journal of Blood Medicine
  80. The consequences of COVID-19 pandemic on patients with monoclonal gammopathy–associated systemic capillary leak syndrome (Clarkson disease)
    Marc Pineton de Chambrun, Quentin Moyon, Stanislas Faguer, G. Urbanski, Alexis Mathian, Noémie Zucman, Marie Werner, Charles Edouard Luyt, Franco Verlicchi, Zahir Amoura et al. · 2021 · The Journal of Allergy and Clinical Immunology In Practice
  81. Systemic immunoglobulin light chain amyloidosis
    2018 · Nature Reviews Disease Primers
  82. Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management.
    María A Vasco-Mogorrón, Jose Antonio Campillo, Adela Periago, Valentín Cabañas, Mercedes Berenguer, María C García-Garay, Lourdes Gimeno, María F. Soto‐Ramírez, María D Martínez-Hernández, Manuel Muro et al. · 2021 · PubMed Central
  83. Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance
    Maximilian Merz, Thomas Hielscher, Korbinian Hoffmann, Anja Seckinger, Dirk Hose, Marc Steffen Raab, Jens Hillengaß, Anna Sophia Jauch, Hartmut Goldschmidt · 2018 · Leukemia
  84. Novel immunotherapies in multiple myeloma
    Ken Ohmine, Ryosuke Uchibori · 2022 · International Journal of Hematology
  85. New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia
    Ramón García‐Sánz, Zachary R. Hunter, Stéphanie Poulain, Marzia Varettoni, Roger G. Owen · 2023 · Expert Review of Hematology
  86. The Pathophysiological and Therapeutic Implications of Cardiac Light-Chain Amyloidosis Compared With Transthyretin Amyloidosis
    Joel D. Schilling, Mario Nuvolone, Giampaolo Merlini · 2024 · JACC Heart Failure
  87. The Danish Lymphoid Cancer Research (DALY-CARE) Data Resource: The Basis for Developing Data-Driven Hematology
    Christian Brieghel, Mikkel Werling, Casper Møller Frederiksen, Mehdi Parviz, Caspar da Cunha‐Bang, Tereza Faitová, Rebecca Svanberg Teglgaard, Noomi Vainer, Thomas Lacoppidan, Emelie Curovic Rotbain et al. · 2025 · Clinical Epidemiology
  88. Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma
    Natalya Plakhova, Vasilios Panagopoulos, Melissa D Cantley, Laura J. Trainor, Duncan R. Hewett, Kimberley C. Clark, Jo Gardiner, Angelina Yong, Cindy Lee, Noemi Horvath et al. · 2025 · Leukemia
  89. Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis
    Beatriz Gámez, Claire M. Edwards · 2018 · Current Osteoporosis Reports
  90. Peripheral Neuropathies Associated With Monoclonal Gammopathies
    Elie Naddaf, Michelle L. Mauermann · 2020 · CONTINUUM Lifelong Learning in Neurology
  91. Comparison of Monoclonal Gammopathies Linked to Poliovirus or Coxsackievirus vs. Other Infectious Pathogens
    Jean Harb, Nicolas Mennesson, Cassandra Lepetit, Maeva Fourny, Margaux Louvois, Adrien Bosseboeuf, Sophie Allain‐Maillet, Olivier Decaux, Caroline Moreau, Anne Tallet et al. · 2021 · Cells
  92. Mono/polyclonal free light chains as challenging biomarkers for immunological abnormalities
    Cecilia Napodano, Krizia Pocino, Francesca Gulli, Elena Giulia Rossi, Gian Ludovico Rapaccini, Mariapaola Marino, Umberto Basile · 2022 · Advances in clinical chemistry
  93. Monoclonal gammopathy of increasing significance: time to screen?
    Lucia Chen, Mark Trehane Drayson, Christopher M. Bunce, Karthik Ramasamy · 2022 · Haematologica
  94. Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
    Patrizia Mondello, Jonas Paludo, Joseph P. Novak, Kerstin Wenzl, Zhi-Zhang Yang, Shahrzad Jalali, Jordan Edward Krull, Esteban Braggio, Surendra Dasari, Michelle K. Manske et al. · 2022 · Clinical Cancer Research
  95. Monoclonal gammopathy of renal significance: Multidisciplinary approach to diagnosis and treatment
    Sabine Karam, Mohammad Haidous, Iman Abou Dalle, Amélie Dendooven, Nour M. Moukalled, Amaryllis H. Van Craenenbroeck, Ali A. Bazarbachi, Ben Sprangers · 2023 · Critical Reviews in Oncology/Hematology
  96. The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and of renal significance
    Krzysztof Batko, Jolanta Małyszko, Artur Jurczyszyn, David H. Vesole, Morie Abraham Gertz, Xavier Leleu, Anna Suska, Marcin Krzanowski, Władysław Sułowicz, Jacek Stanisław Małyszko et al. · 2018 · Nephrology Dialysis Transplantation
  97. Cardiac Amyloidosis for the Primary Care Provider: A Practical Review to Promote Earlier Recognition of Disease
    Kathleen W. Zhang, Srilakshmi Vallabhaneni, Jose A. Alvarez-Cardona, Ronald J. Krone, Joshua D. Mitchell, Daniel John Lenihan · 2021 · The American Journal of Medicine
  98. Feasibility of a Biomarker‐Based Screening for Pre‐Symptomatic AL Amyloidosis in Patients With Intermediate/High‐Risk MGUS
    Silvia Mangiacavalli, Paolo Milani, Claudio Salvatore Cartia, Marzia Varettoni, Michele Palumbo, Marco Basset, Valeria Masoni, Mario Nuvolone, Andrea Foli, Virginia Valeria Ferretti et al. · 2024 · American Journal of Hematology
  99. Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution
    Meletios Athanasios Dimopoulos, Ioannis Ntanasis‐Stathopoulos, Despina Fotiou, Foteini Theodorakakou, Eirini Solia, Vasiliki Spiliopoulou, Panagiotis Malandrakis, Erasmia Psimenou, Stavroula Giannouli, Nikolaos Kanellias et al. · 2025 · American Journal of Hematology
  100. Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study
    Ling Ma, Shuang Xu, Jianhua Qu, Jian Hou, Yang Wang, Lei Wen, Yang Liu, Ying Kang, Ming Yan Jiang, Weijun Fu et al. · 2018 · Hematological Oncology